NFE2L2 and early-onset autosomal dominant Alzheimer disease: In the Senescence Accelerated Mouse‐Prone 8 (SAMP8) mouse, an Alzheimer's disease mouse model, GSK‐3β inhibition caused NRF2 activation and decreased oxidative stress, together with reduced Tau phosphorylation and improved learning and memory (Farr et al, 2014).